Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Down 39.6% in December

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 9,326 shares, a decline of 39.6% from the December 15th total of 15,440 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 33,508 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily trading volume, of 33,508 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the company’s shares are short sold.

Hedge Funds Weigh In On Lisata Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cerity Partners LLC bought a new stake in Lisata Therapeutics in the 2nd quarter valued at about $32,000. CIBC Bancorp USA Inc. acquired a new stake in Lisata Therapeutics in the third quarter valued at approximately $37,000. Finally, Ground Swell Capital LLC bought a new stake in shares of Lisata Therapeutics during the third quarter valued at approximately $62,000. Institutional investors own 8.94% of the company’s stock.

Wall Street Analysts Forecast Growth

LSTA has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Wednesday, October 8th. Zacks Research downgraded shares of Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.50.

Lisata Therapeutics Trading Down 0.9%

NASDAQ LSTA traded down $0.02 during trading hours on Friday, hitting $2.16. 34,994 shares of the company’s stock were exchanged, compared to its average volume of 38,698. The firm has a market cap of $19.05 million, a price-to-earnings ratio of -1.01 and a beta of 1.11. The stock has a 50-day simple moving average of $2.03 and a 200 day simple moving average of $2.33. Lisata Therapeutics has a 1-year low of $1.81 and a 1-year high of $4.11.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.05. On average, sell-side analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current fiscal year.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.